HollisterStier Contract Manufacturing signed a construction, validation and supply agreement with MGI Pharma, Inc. Spokane, WA-based HollisterStier is building a new compounding suite for MGI Pharma to accommodate the manufacturing process for ZYC101a, an investigational therapeutic designed to augment the body’s defensive response to human papillomavirus (HPV).

Preliminary engineering plans for the suite are currently underway and the company expects to have construction complete in May of this year. Validation of the new 1,000-sq.-ft. compounding suite will take the remainder of the year.

“HollisterStier is pleased to partner with MGI Pharma on this project. Clearly this is another example of how HollisterStier’s technical expertise can readily accommodate our contract customers in an extremely timely manner,” said Anthony Bonanzino, president and chief executive officer.

William Vincek, senior vice president, technical operations of MGI Pharma, said, “HollisterStier Contract Manufacturing is an excellent partner for the development and management of complex manufacturing processes. With their technical knowledge supporting our unique processes and scale, we believe HollisterStier will be able to meet the needs of our current clinical plans and of our commercial launch projections.”